Intravenous immunoglobulin with enhanced polyspecificity improves survival in experimental sepsis and aseptic systemic inflammatory response syndromes

Molecular Medicine

Volumn 21, Issue , 2015, Pages 1002-1010

  Djoumerska Alexieva, Iglika ^a   Roumenina, Lubka ^b   Pashov, Anastas ^a   Dimitrov, Jordan ^a,b   Hadzhieva, Maya ^a   Lindig, Sandro ^c   Voynova, Elisaveta ^d   Dimitrova, Petya ^a   Ivanovska, Nina ^a   Bockmeyer, Clemens ^e   Stefanova, Zvetanka ^a   Fitting, Catherine ^f   Bläss, Markus ^c   Claus, Ralf ^c   Von Gunten, Stephan ^g   Kaveri, Srini ^b   Cavaillon, Jean Marc ^f   Bauer, Michael ^c   Vassilev, Tchavdar ^a,c  

^a INSTITUTE OF MICROBIOLOGY   (Bulgaria)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

^c JENA UNIVERSITY HOSPITAL   (Germany)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f INSTITUT PASTEUR   (France)

^g UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; COMPLEMENT; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; FERROUS ION; GAMMA INTERFERON; IMMUNOGLOBULIN; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 22; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1GAMMA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOTTING TIME; COMPLEMENT SYSTEM; CONTROLLED STUDY; DRUG EFFICACY; ENDOTOXEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; PROTEIN BLOOD LEVEL; SEPSIS; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SURVIVAL RATE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 84975124897     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2014.00224     Document Type: Article

References (38)

1. Angus DC, van der Poll T. (2013) Severe sepsis and septic shock. N. Engl. J. Med. 369:840-51.
2. Cavaillon J-M, Adrie C (eds.). (c2009) Sepsis and Non-infectious Systemic Inflammation: From Biology to Critical Care. Weinheim: Wiley-VCH Verlag.
3. The INIS Collaborative Group. (2011) Treatment of neonatal sepsis with intravenous immune globulin. N. Engl. J. Med. 365:1201-11.
4. Rittirsch D, Flierl MA, Ward PA. (2008) Harmful molecular mechanisms in sepsis. Nat. Rev. Immunol. 8:776-87.
5. Bouvet J, et al. (2001) Induction of natural autoantibody activity following treatment of human immunoglobulin with dissociating agents. J. Autoimmun. 16:163-72.
6. Xiao W, et al. (2011) A genomic storm in critically injured humans. J. Exp. Med. 208:2581-90.
7. Kazatchkine MD, Kaveri SV. (2001) Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N. Engl. J. Med. 345:747-55.
8. Lutz HU (ed.). (c2012) Naturally Occurring Antibodies (NAbs). New York: Springer Science+ Business Media; (Austin) TX: Landes Bioscience. pp. 267.
9. Laupland KB, Kirkpatrick AW, Delaney A. (2007) Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: A systematic review and meta-analysis. Crit. Care Med. 35:2686-92.
10. Soares MO, et al. (2012) An evaluation of the feasibility, cost and value of information of a multicentre randomised controlled trial of intravenous immunoglobulin for sepsis (severe sepsis and septic shock): Incorporating a systematic review, meta-analysis and value of information analysis. Health Technology Assessment. 16:1-186.
11. Werdan K, et al. (2007) Score-based immunoglobulin G therapy of patients with sepsis: The SBITS study. Crit. Care Med. 35:2693-701.
12. Djoumerska I, Tchorbanov A, Pashov A, Vassilev T. (2005) The autoreactivity of therapeutic intravenous immunoglobulin (IVIG) preparations depends on the fractionation methods used. Scand. J. Immunol. 61:357-63.
13. Djoumerska-Alexieva IK, et al. (2010) Exposure of IgG to an acidic environment results in molecular modifications and in enhanced protective activity in sepsis. FEBS J. 277:3039-50.
14. Pavlovic S, et al. (2011) Intravenous immunoglobulins exposed to heme (heme IVIG) are more efficient than IVIG in attenuating autoimmune diabetes. Clin. Immunol. 138:162-71.
15. Dimitrov JD, et al. (2006) Ferrous ions and reactive oxygen species increase antigen-binding and anti-inflammatory activities of immunoglobulin G. J. Biol. Chem. 281:439-46.
16. Dimitrov J, et al. (2007) Antibodies use heme as a cofactor to extend their pathogen-eliminating activity and to acquire new effector functions. J. Biol. Chem. 282:26696-706.
17. McIntyre J, Wagenknecht D, Faulk W. (2006) Redox-reactive autoantibodies: Detection and physiological relevance. Autoimmun. Rev. 5:76.
18. Djoumerska-Alexieva IK, Dimitrov JD, Nacheva J, Kaveri SV, Vassilev TL. (2009) Protein destabilizing agents induce polyreactivity and enhanced immunomodulatory activity in IVIg preparations. Autoimmunity. 42:365-7.
19. Hubbard WJ, et al. (2005) Cecal ligation and puncture. Shock. 24 Suppl 1:52-7.
20. Volman TJ, Hendriks T, Goris RJ. (2005) Zymosan-induced generalized inflammation: Experimental studies into mechanisms leading to multiple organ dysfunction syndrome. Shock. 23:291-7.
21. Ivanovska ND, et al. (2008) Properdin deficiency in murine models of nonseptic shock. J. Immunol. 180:6962-9.
22. Haeffner-Cavaillon N, Klein M, Dorrington KJ. (1979) Studies on the Fc gamma receptor of the murine macrophage-like cell line P388D1. I. The binding of homologous and heterologous immunoglobulin G1. J. Immunol. 123:1905-13.
23. Ward PA, Gao H. (2009) Sepsis, complement and the dysregulated inflammatory response. J. Cell Mol. Med. 13:4154-60.
24. Markiewski MM, DeAngelis RA, Lambris JD. (2008) Complexity of complement activation in sepsis. J. Cell Mol. Med. 12:2245-54.
25. Xu J, et al. (2009) Extracellular histones are major mediators of death in sepsis. Nat. Med. 15:1318-21.
26. Basta M. (2008) Ambivalent effect of immunoglobulins on the complement system: Activation versus inhibition. Mol. Immunol. 45:4073-9.
27. Basta M, Fries LF, Frank MM. (1991) High doses of intravenous Ig inhibit in vitro uptake of C4 fragments onto sensitized erythrocytes. Blood. 77:376-80.
28. Devran O, et al. (2012) C-reactive protein as a predictor of mortality in patients affected with severe sepsis in intensive care unit. Multidiscip. Respir. Med. 7:47-52.
29. Tang BM, Huang SJ, McLean AS. (2010) Genome-wide transcription profiling of human sepsis: A systematic review. Crit. Care. 14:R237.
30. Coutinho A, Avrameas S. (1992) Speculation on immunosomatics: Potential diagnostic and therapeutic value of immune homeostasis concepts. Scand. J. Immunol. 36:527-32.
31. Cavaillon JM, Adib-Conquy M. (2007) Determining the degree of immunodysregulation in sepsis. Contrib. Nephrol. 156:101-11.
32. Sigounas G, Harindranath N, Donadel G, Notkins AL. (1994) Half-life of polyreactive antibodies. J. Clin. Immunol. 14:134-40.
33. Matzinger P. (2002) The danger model: A renewed sense of self. Science. 296:301-5.
34. Seong SY, Matzinger P. (2004) Hydrophobicity: An ancient damage-associated molecular pattern that initiates innate immune responses. Nat. Rev. Immunol. 4:469-78.
35. Rauch PJ, et al. (2012) Innate response activator B cells protect against microbial sepsis. Science. 335:597-601.
36. Djoumerska-Alexieva I, Pashova S, Vassilev T, Pashov A. (2013) The protective effect of modified intravenous immunoglobulin in LPS sepsis model is associated with an increased IRA B cells response. Autoimmun. Rev. 12:653-6.
37. Seok J, et al. (2013) Genomic responses in mouse models poorly mimic human inflammatory diseases. PNAS. 110:3507-12.
38. Takao K, Miyakawa T. (2015) Genomic responses in mouse models greatly mimic human inflammatory diseases. PNAS. 112:1167-72.